'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds

🤖AI Özeti

A recent report by Deloitte highlights the growing dominance of obesity drugs in the pharmaceutical sector, indicating that these assets now account for 25% of total forecast sales in the late-stage pipeline. In contrast, oncology drugs have seen a decline, dropping to 20%. This shift raises concerns about the sustainability of the pharmaceutical market, as the rapid growth in obesity treatments may lead to a 'bubble effect'.